Abbott announced on May 27 that it has secured the CE Mark for Libre Duo and Libre Duo 10 Day, the world’s first dual glucose-ketone sensing technology designed for people with diabetes. The new systems continuously measure both glucose and ketone levels every minute, providing real-time data to support daily diabetes management and help detect rising ketones that can lead to diabetic ketoacidosis.
The company said this is the first time people with diabetes will be able to monitor ketones without traditional blood or urine tests. Abbott plans to launch Libre Duo systems in select European countries later this year. The sensors are intended to reduce reliance on single-point-in-time testing by offering continuous monitoring and alerting users of rising ketones so they can act sooner if needed.
Libre Duo delivers up to 15 days of wear for adults ages 18 and older, while Libre Duo 10 Day offers up to 10 days of wear for people ages two and older. Both sensors are designed for integration with Abbott’s Libre digital health ecosystem, enabling users to share their data with caregivers and healthcare providers. The company is also working with pump manufacturers so automated insulin delivery systems can connect with these sensors.
Chris Scoggins, executive vice president of Abbott’s diabetes care business, said, “Abbott has a long-established pattern of setting the pace in health tech innovation. People living with diabetes routinely tell us that the risk of serious complications is a constant part of everyday life. Our Libre Duo systems offer people with diabetes, families and healthcare providers clearer, earlier information about what’s happening inside their body, allowing them to act sooner when safety matters most.”
Libre Duo aligns with recommendations from an international expert consensus paper from Breakthrough T1D supporting continuous ketone monitoring as part of diabetes management. Data cited by Abbott show diabetic ketoacidosis rates have increased over recent years among both Type 1 and Type 2 diabetics; DKA now accounts for more hospitalizations than hypoglycemia in the United States, according to research published in Diabetes Care and statistics from the Centers for Disease Control.
Libre Duo systems are not yet cleared or available for sale in the United States.
